Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences is supported by a differentiated pipeline with multiple shots on goal, led by ABI-6250, which now extends beyond HDV into PBC and PSC with a planned Phase 2 basket study in 1Q27 and data in 1H28, while HDV Phase 2 is expected by year-end 2026. The company’s lead assets also gained credibility from EASL 2026 data and Gilead’s selection of GS-1179 to advance into Phase 2 for recurrent genital herpes by year-end 2026, with added HIV PrEP optionality expanding the commercial ceiling. Financially, it ended 2Q26 with $320.4 million in cash and investments and expects funding into 2029, including the first $75 million Gilead collaboration extension payment due in 4Q26.

Assembly Biosciences is viewed negatively because, despite having $226.6M in cash at the end of 1Q 2026 and a May 2026 financing that raised about $115M, the company still appears likely to require more capital before achieving durable profitability. Management’s cash runway into 2028 is helpful but excludes potential GILD payments and warrant exercises, while the expectation of no continuing profitability until 2032 implies substantial financing risk and possible dilution from additional offerings. On top of that, setbacks for ABI-5366, ABI-1179, or ABI-6250, along with reimbursement or commercialization problems, could materially weaken future sales and valuation.